Podcasts

Safety and value driving Phase IV growth at CROs; EVP

Safety and value driving Phase IV growth at CROs; EVP

By Gareth Macdonald

Increased focus on post-market safety and value has resulted in CROs handling more Phase IV work, according to a PharmaNet EVP, and this trend may continue as regulators seek real world evidence.

INC forms ePRO partnership with invivodata

INC forms ePRO partnership with invivodata

By Nick Taylor

INC Research is partnering with invivodata to add ePRO to its offering, selecting the eClinical firm over its competitors in part because it understands the “aggressive” approach the CRO takes.

Centralising ECG trial data can cut costs 40%, says ERT

Centralising ECG trial data can cut costs 40%, says ERT

By Gareth Macdonald

E Research Technology (ERT) launches Centralised Cardiac Safety 2.0 (CCS 2.0) service for ECG data and says approach improves efficiency, cuts costs and helps sponsors reach database lock quicker than distributed model.

Quintiles opens Nairobi office

Quintiles opens Nairobi office

By Gareth Macdonald

Contract services giant Quintiles has continued its expansion in Africa with a new clinical research services office in Nairobi, Kenya.

Electronic submission offers benefits for pharma, says ISI

Electronic submission offers benefits for pharma, says ISI

By Gareth Macdonald

Drug firms continue to make basic errors in their electronic submissions according to French regulatory group the AFSSAPS, which said recently that it returns half the NeeS dossiers it receives as they do not meet basic validation standards.

Informex – companies hope for a brighter 2010

Informex – companies hope for a brighter 2010

By Nick Taylor

There are signs that 2010 will be a better year for the fine and custom chemistry industry but companies at Informex remained cautious and are planning accordingly.

MENA emerging as trial destination says ClinTec CEO

MENA emerging as trial destination says ClinTec CEO

By Gareth Macdonald

Improving healthcare infrastructure across the region and a large treatment-naïve patient population makes the Middle East and North Africa (MENA) an increasingly attractive destination for drug trials says ClinTec CEO Rabinder Buttar.

Follow us

Products

View more

Webinars